Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has earned an average recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $31.00.

MPLT has been the topic of several research analyst reports. Leerink Partners began coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. Leerink Partnrs raised shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Stifel Nicolaus assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th.

Maplight Therapeutics Price Performance

MPLT opened at $20.35 on Wednesday. Maplight Therapeutics has a fifty-two week low of $12.24 and a fifty-two week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.